anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a manufacturing method that permits the efficient acquisition of a composition comprising pinitol of high purity in a high content by a simple operation.  <P>SOLUTION: A solvent such as water or ethanol is incorporated with a freeze-dried powder of a soybean pod. The powder is crushed by a mixer and is subsequently subjected to extraction for 24 hours with stirring at room temperature using a magnetic stirrer. The resulting treated liquid is subjected to suction filtration through a filter paper (No.5C manufactured by ADVANTEC TOYO Co.) using diatomaceous earth as a filter aid. The resultant extract liquid is freeze-dried and crushed by a mill into a powdery composition containing pinitol.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
PURPOSE:To achieve higher operability by providing a record information retrieving means which can retrieve record information of a record on the side of an endoscope body to facilitate the retrieval of the record information of the recorder while allowing displaying thereof on a display means of the body. CONSTITUTION:A record information retrieving means 4 is made up of a control 4a to control the record information retrieving means 4 through a central control section 7, a recording means 4b to record information retrieved and an input means 4c to input retrieving information, operating information and the like and made able to retrieve record information of a recorder 6. An operator starts inspection with an endoscope and for example, an internal wall of a stomach is displayed direct on a TV monitor 5a as inspection image 8. Then, when a past inspection image of a testee is desired to be referred, the operator inputs identifying information of the lesion to be inspected from the input means 4a. The information is transmitted to an information recorder 6 to retrieve the past inspection image involved of the body to be inspected from an internal recording means 6a or an external recording means 6b and record information retrieved is recorded by the recording means 4b. At the same time, for example, the record information with a new inspection data is displayed on the TV monitor 5a as past inspection image 9.
Biologic-naïve rheumatoid arthritis (RA) patients who fulfilled the 2010 criteria of the American College of Rheumatology (ACR) for RA were enrolled. All patient were randomized to a 6-month treatment with either oral DXM \[dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan) with T1/2 = 7.75h, Tmax = 4.83h, Cmax = 14.6 ng mL-1 and mean residual time = 5.86 h, 120mg per day with once daily dose taken after breakfast\] or placebo pills with the same appearance as DXM tablets. The randomization was performed by the pharmacy of the Taichung Veterans General Hospital. Non-study medications were not changed during the course of study.

Twenty-four patients received add-one DXM therapy and the other 24 patients received traditional DMARDs alone in stable dose. Disease activity was assessed by the 28-joint disease activity score (DAS28) before starting add-on DXM therapy (as a baseline) and at the end of 6 months of therapy with or without add-on DXM. Patients were categorized as good, moderate or poor responders based on the amount of change in the DAS28 and the level of DAS28 reached. Good responders were defined as patients who had a decrease in DAS28 from baseline (∆DAS28)\>1.2 and a DAS28≦3.2 at evaluation time; moderate responders had either ∆DAS28\>1.2 and a DAS28\>3.2 or ∆DAS28 of 0.6-1.2 and a DAS28≦5.1 at evaluation time; and poor responders were those who had either ∆DAS28\<0.6 or a DAS28\>5.1 at evaluation time.
chemoradiotherapy-induced myelosuppression (CIM) is the most common adverse event of concurrent chemoradiotherapy for esophageal cancer, often leading to reduction, delay or even cessation of chemotherapeutic agents. Clinical treatments for CIM mainly include various hematopoietic growth factors and blood transfusion. However, these interventions target only a single spectrum of blood cells and are susceptible to concomitant adverse events such as bone pain, thrombosis, and fever. Trilaciclib is a potent, transient, reversible CDK4/6 inhibitor and is the world's first innovative drug with lineage-wide myeloprotective effects. Its use in esophageal cancer has not been reported yet. In this study, we investigated the clinical efficacy and safety of trilaciclib in preventing myelosuppression in concurrent chemoradiotherapy for esophageal cancer for the first time.
A method to visualize and correct alignment errors between paired 2D and 3D data sets is described. In a representative embodiment, a display interface used for dental implant planning includes one or more display areas that enable the operator to visualize alignment errors between the paired 2D and 3D data sets. A first display area renders 3D cone beam data. A second display area renders one or more (and preferably three (3) mutually orthogonal views) slices of the cone beam data. A third display area displays a view of a 2D scanned surface map (obtained from an intra-oral scan, or the scan of a model). According to a first aspect, the view of the 2D scanned surface map in the third display area is “textured” by coloring the 2D surface model based on the intensity of each 3D pixel (or “voxel”) that it intersects.
A postoperative rehabilitation health manual was provided to patients the day following LEEP surgery. The nursing team, possessing over one year of clinical experience in gynecological nursing and psychological counseling, collaborated with clinicians to deliver health consultation services. They conducted in-person consultations lasting 10-15 minutes during routine outpatient follow-ups at 1, 3, and 6 months post-surgery. Patients were assessed based on the challenges encountered in postoperative rehabilitation and sexual life, and tailored guidance services were administered. Additionally, online counseling and guidance services were offered at 2, 4, or 5 months following surgery.
N6-methyladenosine (m6A) methylation plays a crucial role in various biological processes and the pathogenesis of human diseases. However, its role and mechanism in kidney fibrosis remain elusive. In this study, we show that the overall level of m6A methylated RNA was upregulated and the m6A methyltransferase METTL3 was induced in kidney tubular epithelial cells in mouse models and human kidney biopsies of chronic kidney disease (CKD). Proximal tubule-specific knockout of METTL3 in mice protected kidneys against developing fibrotic lesions after injury. Conversely, overexpression of METTL3 aggravated kidney fibrosis in vivo. Through bioinformatics analysis and experimental validation, we identified β-catenin mRNA as a major target of METTL3-mediated m6A modification, which could be recognized by a specific m6A reader, the insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3). METTL3 stabilized β-catenin mRNA, increased β-catenin protein and induced its downstream profibrotic genes, whereas either knockdown of IGF2BP3 or inhibiting β-catenin signaling abolished its effects. Collectively, these results indicate that METTL3 promotes kidney fibrosis by stimulating the m6A modification of β-catenin mRNA, leading to its stabilization and its downstream profibrotic genes expression. Our findings suggest that targeting METTL3/IGF2BP3/β-catenin pathway may be a novel strategy for the treatment of fibrotic CKD.
Suicide behaviour (SB) represents a major public health problem. In order to improve prevention strategies, a better understanding of the physiopathology of SB is needed. According to a "stress vulnerability" model, people who make a suicide attempt when they are subject to a stress factor (environmental stress, interpersonal difficulties, depression, tobacco, substance abuse...) are those who have a specific vulnerability. Vulnerability factors to SB may be considered in clinical terms (propensity to hopelessness, aggressive impulsivity traits), neurobiological terms (serotoninergic system disorder, especially in the ventral prefrontal cortex-vPFC) and cognitive terms (decision making, cognitive functions mediated by the vPFC and the serotoninergic system). Finally, genetic factors seem also involved in suicide vulnerability. The investigators have conducted a preliminary study which suggests that increased perception of psychic pain during a major depressive disorder increases suicidal ideation and suicidal act. Study about anatomic basis of psychic pain and its triggers represents a relevant theme to understand the suicidal process. Among the classical factors triggering psychic pain and suicidal act, events of social exclusion appears to be crucial. Finally, many data suggests the close relationship between physic and psychic pain.
PURPOSE:To obtain the edge position of a pattern with high stability by replacing the differential value used for calculation of the centroid with the positive difference value obtained by subtracting the prescribed threshold value from said differential value when the position of the centroid obtained by means of the differential value of density showing a level larger than the threshold value. CONSTITUTION:The maximum differential value is obtained from the differential value of plural noticed picture elements and the part having a big change of density in a picture of variable densities is coincident with the area near the pattern edge. Thus this area near the pattern edge can be specified. Then the threshold value that decides an objective area where the calculation for centroid is carried out to obtain the edge position from the maximum differential value is obtained automatically. While the differential value used for calculation of centroid is defined as the difference value {d(Xi)-Tt} obtained by subtracting the threshold value from said differential value. Thus the objective area for calculation of centroid is equal to a part 21 or parts 21 and 23. Therefore the differential value XP is replaced with the difference value {d(Xp)-Tt} which is smaller than the original differential value. Thus it is possible to reduce the effect of said differential value on the result of the calculation of centroid.
The present invention relates to a lactic acid fermented product of  cassia  seeds. The fermented product of the present invention uses  cassia  seeds, which have long been used and have proven their safety without causing side effects. Due to this advantage, the lactic acid fermented product of the present invention is effective in increasing the number, water content, and/or weight of feces. The effects of the lactic acid fermented product according to the present invention are comparable to those of sennoside, which is a therapeutic agent for stimulant constipation and whose use in health functional foods is forbidden because of its side effects, and Dulcolax-S, which is currently commercially available and includes bisacodyl and sodium docusate as active ingredients. Therefore, the lactic acid fermented product of the present invention can be utilized in pharmaceutical compositions for treating or preventing constipation or health functional foods for ameliorating or preventing constipation. In addition, the present invention relates to  Lactobacillus kefiri  strain MJ90. The strain is advantageous for the preparation of the lactic acid fermented product with enhanced activity in the treatment, amelioration or prevention of constipation.
BACKGROUND: The ability to efficiently identify patients at higher risk of poor outcomes after joint replacement would enable limited resources for post-operative follow-up to be directed to those with the greatest clinical need. This is particularly important as joint replacement rates continue to grow internationally, stretching health system capabilities. Patient-reported outcome measures (PROMs) are routinely administered in many settings and offer an opportunity to detect suboptimal patient outcomes early. This study aimed to determine whether hip-specific and generic PROM scores are associated with early revision hip replacement within six to 24 months after the primary procedure.
METHODS: Pre-operative and six-month post-operative PROM scores for patients undergoing primary total hip replacement (THR) were obtained from the Australian Orthopaedic Association National Joint Replacement Registry and Arthroplasty Clinical Outcomes Registry National and linked to revision surgery data. Clinically important improvement was defined using anchor-based thresholds. Associations between PROM scores (hip pain, Oxford Hip Score, HOOS-12, EQ-5D-5L, EQ VAS, patient-perceived change, satisfaction) and revision surgery were evaluated using t-tests, chi-square tests and regression models.
RESULTS: Data were analysed for 21,236 primary THR procedures between 2013 and 2022. Eighty-eight revision procedures were performed at six to 24 months. Patients who were revised had more back pain and worse HOOS-12 scores pre-operatively but between-group differences were small. Worse post-operative PROM scores (hip pain, Oxford, HOOS-12, EQ-5D-5L, EQ VAS) were associated with early revision, after adjusting for age and sex (p < 0.001 for all analyses). Patient dissatisfaction (relative risk (RR) 10.18, 95%CI 6.01-17.25) and patient-perceived worsening (RR 19.62, 95%CI 11.33-33.98) were also associated with a higher likelihood of revision. Patients who did not achieve clinically important improvement in hip pain, function, or quality of life had a higher revision risk (RRs 2.54-5.64), compared with those who did (reference).
CONCLUSION: Six-month hip-specific and generic PROM scores can identify patients at higher risk of early revision surgery. Our data highlight the utility of routine post-operative PROM assessment for signaling suboptimal surgical outcomes.
FIELD: pharmaceutical engineering. SUBSTANCE: composition has anticancer remedy and polyester block copolymer capable of building liquid composition when mixed with water. The block copolymer has a set linear polymer segments with molecular mass of 30-500. At least 80% of bonds linking repeating units in each segment are single ester bonds. The block copolymer has critical micelle-building concentration varying from 0.000001 to 0.5% (mass/volume) or less at 37 C in isotonic aqueous solution. The second composition has the same ingredients but the block copolymer has hydrophobic portion percentage not less than 50% and molecular mass not less than 900 or the critical micelle-building concentration approaching 0.5% (mass/volume) or less under the above mentioned conditions. Treating objects resistant to biological agents, (animal) cancer cases, microbial infections, inhibiting or preventing growth of cancer metastases, eliminating multiple drug resistance of cancer cells is carried out with the first composition. EFFECT: enhanced effectiveness in delivering drugs to tumor cells; restored tumor sensitivity to medicamentous treatment. 57 cl, 9 dwg, 29 tbl
Spatial neglect (SN) frequently occurs in patients who have had a stroke. The problems caused by SN result in patients failing to attend to the space contralateral to the side of the stroke. This failure to attend to half of the patient's field may result in problems with perception, memory, action planning and navigation. These deficits hurt both the patients and their caregivers, and make it difficult for them to resume daily activities as they were before the stroke. More than half of the patients who had SN at admission still had it when discharged from an inpatient rehabilitation facility.

This study examines a new behavioral treatment, where the clinician and the caregiver work together to provide better treatment. The family members will engage in frequent meetings with clinicians, set goals, learn about SN and coping strategies and have the patient to perform easy, safe treatment exercises. The study will compare this Family-Clinician Collaboration with the inpatient treatment control. This study will compare the groups in measures of spatial neglect and independence in the patients and measures of caretaker burden and mental health in family members. Participants will also report on their overall opinions of the new treatment condition.
Alloimmunisation against the RhD (RH) red cell surface antigen is the commonest cause of haemolytic disease of the fetus and newborn. It can be avoided by anti D immunoglobulin administration (RhIg). At the end of year 2005, new recommendations about anti-D prophylaxis in France proposed that all RhD negative pregnant women should be given anti-D immunoglobulin at 28 weeks' gestation. However, about one third of these women would be carrying an RhD negative fetus and would receive the treatment unnecessarily. A non-invasive fetal RHD typing kit, CE labelled since June 2007, is available and could be proposed to all RhD negative pregnant women. Applicable from the end of the first trimester of pregnancy on fetal DNA isolated from maternal plasma, this assay allows RhIg to be specifically injected to unsensitized pregnancies with RhD positive fetus only, and to promote the use of antenatal RhIg prophylaxis in a rational approach with economical and ethical impact.The study is divided in two sub-studies. The first one is an economical and performance comparison between two antenatal management strategies of RhD negative pregnant women: the first one will comprise non invasive RhD fetal typing during the second trimester of pregnancy (GENIFERH 1 RhD typing group), and the second will be a conventional management, i.e. without RHD fetal typing (GENIFERH 1 control group). The two groups will consist of 13 maternity wards spread over French territory. The second study (GENIFERH 2) is an evaluation of RhD fetal typing diagnostic performance and biological feasibility in routine antenatal practice with development of knew technical support; it will be based on more than 3500 fetal genotypings performed during one year by the five laboratories participating at the two studies.
Suicide is a significant clinical and public health issue, with about 50% of individuals who die by suicide being diagnosed with a mood disorder within the year prior to their death, and 27% of suicide deaths attributable to depression. This indicates a higher risk of suicidal ideation (SI) during depressive episodes compared to the general population, highlighting the urgent need for effective interventions to rapidly alleviate SI and reduce suicide mortality rates. Currently, the rapid intervention measures for suicidal symptoms primarily include electroconvulsive therapy (ECT)/modified electroconvulsive therapy (MECT). However, due to the complexity of the procedures and certain risks involved, some institutions cannot perform this treatment. Additionally, cognitive impairments and other adverse reactions following the treatment may lead to patient noncompliance, thus there is a clinical urgency to find a simple, effective, and safe intervention to rapidly treat SI. Esketamine has been proven in past studies to have a rapid effect in relieving SI, but there is a lack of large-scale clinical studies to clarify the efficacy of esketamine due to short clinical observation periods. Therefore, there is an urgent need to conduct large-scale, multicenter RCT studies to verify whether esketamine is as applicable as ECT/MECT for rapid improvement of suicidal ideation in individuals with depressive episodes of mood disorders. This holds significant clinical importance and will provide key evidence-based foundations for future guidelines.

This study, through a randomized controlled trial, treats patients with suicidal ideation (SI) during depressive episodes of mood disorders using esketamine or modified electroconvulsive therapy (MECT). It compares the rapid anti-suicidal effects and adverse reactions of the two treatment modalities, providing evidence-based data for the clinical application of esketamine.
When you join the Dr. Biolyse® Therapy Group, you will be given electrical signal therapy with the Dr. Biolyse® device. Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. The treatment protocol to be applied to DBTG patients consists of device therapy and daily fluid support therapy. No medication or different device applications are performed.
PROBLEM TO BE SOLVED: To produce an ornament combining magnetism and perfuming proper ties by sintering magnetic metal powder composed of a gold alloy or a platinum alloy into a porous state, magnetizing it and impregnating it with perfume. SOLUTION: A gold alloy or platinum alloy material is pulverized by a centrifugal atomizing method and is formed into spherical fine powder 1 of 1 to 106 μm grain size. A molding pattern for making a molded article 2 having a complicated shape is produced by a lost wax method, and, by using the molding pattern, a gypsum mold 3 is formed in a vessel 4. This gypsum mold 3 is applied with suitable vibration, and the spherical fine powder 1 is securely filled into the gypsum mold 3. Next, it is sintered and heated in a noncompressive state to form a molded body sintered into a porous state, which is subjected to solution heat treatment, aging treatment and magnetizing treatment in succession and is subsequently impregnated with perfume such as a medical perfume.  In this way, the molded article 2 having a complicated shape enough in aesthetic properties and having the secure permeability and suitable emissivity of the perfume can be obtd.
<P>PROBLEM TO BE SOLVED: To obtain a high purity wax ester practically not containing triglycerides from the liver oil of longfin codling (Laemonema longipes).  <P>SOLUTION: The invention relates to a process for obtaining a high purity wax ester by purifying the liver oil of longfin codling. The process is presented involving a step to isolate the wax ester from the liver oil by molecular distillation and a step to deodorize the isolated wax ester. The process is also presented including a step comprising passing the liver oil through an absorbent, placing the absorbent in the flow of hexane and isolating the wax ester from the fraction eluted by the hexane. A cosmetic, a drug and a quasi-drug containing the highly unsaturated wax ester obtained by the process are presented.  <P>COPYRIGHT: (C)2006,JPO&NCIPI